HBM Healthcare Investments AG Stock Swiss Exchange

Equities

HBMNE

CH0257717097

Investment Management & Fund Operators

Delayed Swiss Exchange 08:10:24 2024-06-17 am EDT 5-day change 1st Jan Change
211.5 CHF +0.48% Intraday chart for HBM Healthcare Investments AG +0.71% +16.34%
Sales 2025 * 76.9M 86.14M Sales 2026 * 132M 148M Capitalization 1.42B 1.59B
Net income 2025 * 51M 57.13M Net income 2026 * 107M 120M EV / Sales 2025 * 16.9 x
Net cash position 2025 * 117M 131M Net cash position 2026 * 126M 141M EV / Sales 2026 * 9.77 x
P/E ratio 2025 *
28.5 x
P/E ratio 2026 *
13.5 x
Employees 700
Yield 2025 *
3.48%
Yield 2026 *
3.84%
Free-Float 81.48%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.48%
1 week+0.71%
Current month+1.20%
1 month+4.70%
3 months+10.97%
6 months+20.86%
Current year+16.34%
More quotes
1 week
206.00
Extreme 206
213.00
1 month
198.00
Extreme 198
213.00
Current year
156.40
Extreme 156.4
213.00
1 year
148.20
Extreme 148.2
256.50
3 years
148.20
Extreme 148.2
256.50
5 years
140.80
Extreme 140.8
256.50
10 years
89.80
Extreme 89.8
256.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 01-06-30
Director of Finance/CFO 54 11-10-31
Corporate Secretary 60 -
Members of the board TitleAgeSince
Chairman 68 09-05-31
Director/Board Member 69 21-06-17
Director/Board Member 52 11-12-31
More insiders
Date Price Change Volume
24-06-17 211.5 +0.48% 400
24-06-14 210.5 -0.47% 600
24-06-13 211.5 +0.24% 600
24-06-12 211 -0.24% 600
24-06-11 211.5 +0.71% 600

Delayed Quote Swiss Exchange, June 17, 2024 at 08:10 am EDT

More quotes
HBM Healthcare Investments AG is a Switzerland-based venture capital company investing in emerging companies, mainly from the biotechnology and human medicine, diagnostics, as well as medical technology sectors. The Company focuses on unlisted companies, with two-thirds of assets being invested in private companies that offer high value-creation potential. As a holding company, it is involved in the acquisition, disposal and management of a diversified portfolio, as well as in financing and supporting the portfolio firms as a key partner. It focuses on companies with products either at an advanced stage of development or already available on the market. The primary investment areas are Western Europe and the United States. The Company's portfolio includes approximately 25 companies. As of March 31, 2012, the Company had six wholly owned subsidiaries, including three subsidiaries on Cayman Islands, two Barbados-based subsidiaries and a subsidiary in the United States.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
206.5 CHF
Average target price
236 CHF
Spread / Average Target
+14.29%
Consensus

Annual profits - Rate of surprise